A team of researchers from Johns Hopkins University are calling on people who use psychedelics to enroll for their new study that is geared at understanding the real-world effects of taking psychedelic substances like shrooms (magic mushrooms).
The Johns Hopkins researchers are working together with Unlimited Sciences, a Denver-based nonprofit which is funding this “real-world” study. The intention is to get insights into the factors which impact psychedelic trips and the outcomes of those trips. To this end, the researchers are asking anyone who plans, for whatever reason, to take psychedelics, to enroll. They are also open to people taking psychedelics in different settings, such as during festivals, in nature and during individual psychedelic trips.
This study is taking the investigation of psychedelics beyond a laboratory since the people who use these substances don’t use them in the highly controlled laboratory setting. The research is open to adults who can use English. Those individuals should also be having an intention of using psilocybin within the coming six months. Interested participants can sign up at www.UnlimitedSciences.org/our-study/.
However, intending participants are advised that they should be ready and willing to take about five surveys in the course of the research. One of those surveys will come a fortnight before the day the research participant plans to take psilocybin. A second survey is planned in the hours just before the participant takes the psychedelic and another will be administered a few days after the study subject takes their psilocybin dose. The final two surveys will come several weeks or months after the day the participant took psilocybin. Completing each of these surveys is anticipated to require 10-30 minutes.
The surveys will center on the state of mind (“set”) and environment (“setting”) during which psilocybin is taken by each participant. The personal experiences shared will help the researchers to identify the variables around psilocybin use and its effects (health or otherwise) upon the users.
Johns Hopkins University has been involved in psychedelics research for more than a decade, and they launched a first of a kind psychedelics research center (Center for Psychedelics and Consciousness Research) last year. The purpose of that center is to investigate the possible therapeutic uses of psychedelics, such as helping people to quit smoking or to treat depression.
A press release from Unlimited Sciences states that the researchers will identify areas of future research, including clinical trials, from the data they collect during this real-world study.
Advocates for the responsible use of psychedelics have been registering successes in various jurisdictions. For example, voters in Washington, D.C. will have a chance to decide on a ballot measure seeking to decriminalize fungus and plant-based psychedelic substances like ibogaine and magic mushrooms. In Canada, four end-stage cancer patients got permission to use psilocybin in a landmark decision for exemption to the country’s laws on psychedelics.
All these developments show that a psychedelics renaissance could be taking shape, and you can bet that companies like Mind Medicine (NEO: MMED) (OTCQB: MMEDF) will be in the thick of this rebirth.
About PsychedelicNewsWire
PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.
To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.PsychedelicNewsWire.com
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer
Do you have questions or are you interested in working with PNW? Ask our Editor
PsychedelicNewsWire (PNW)
San Francisco, California
www.PsychedelicNewsWire.com
415.949.5050 Office
Editor@PsychedelicWire.com
PsychedelicNewsWire is part of the InvestorBrandNetwork.